NCT03997617Completed
Personalized Functional Profiling in Metastatic Gastrointestinal Cancer or Recurrent Glioblastoma Patients in Luxembourg.
Pilot Study to Explore the Integrated Personalized Functional Profiling (PFP) for Cancer Patients With Metastatic Gastrointestinal Cancer (mGIC) or Recurrent Glioblastoma (rGBM) in Luxembourg
Source: ClinicalTrials.gov · Last updated 13 Jun 2025
Brief summary (registry, in English)
The investigators are developing a novel standardized and centralized approach named Integrated Personalized Functional Profiling (PFP) in Luxembourg. Based on recent improvements in cancer biopsy-derived 3D-culture technologies the PFP process will screen patient derived cells (PDCs) with FDA/EMA-approved drugs to generate personalized functional response profiles. The selected drug through PFP technology will provide personalized treatment recommendation for the patient. This pilot study will evaluate the clinical feasibility of setting-up an effective workflow as a first step. Outcomes from this study will be used subsequently to help plan the clinical validation of the implementation of PFP.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 57 (actual)
- First submitted
- 11 Mar 2019
- Start date
- 11 Mar 2019
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Luxembourg Institute of Health
- Diseases
- Glioblastoma
- NCT number
- NCT03997617
What you commit to
- Study type: Interventional
- Participants enrolled: 57
- From 11 Mar 2019 to the primary completion date, 31 Dec 2024
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known active Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection
- Uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc), psychological, familial, sociological, or geographical conditions that do not allow compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol
- In mGIC arm, patient with non-adenocarcinoma gastrointestinal cancer
Other
- For female patient, being pregnant, planning a pregnancy or breastfeeding
- No fresh and viable tumor material available
- Patient unable to understand and consent himself
Who the study is looking for
- Patient with recurrent Glioblastoma (rGBM) or with metastatic gastrointestinal cancer (mGIC), i.e. adenocarcinoma (any grade) of stomach, liver, pancreas, small intestine, colon, rectum
- The patient has received previous cancer treatment for mGIC or rGBM
- Male or female ≥ 18 years
- Life expectancy ≥ 12 weeks
- Histologically or cytologically confirmed diagnosis for mGIC or recurrence of a glioblastoma, WHO grade IV
- For women of childbearing potential, a negative pregnancy test documented prior to the screening visit is required
- Signed Inform Consent Form before any study related procedure
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre hospitalier de Luxembourg Coordinator of this site? Confirm its status | Luxembourg | Luxembourg | Unknown status |
| Hôpitaux Robert Schmuan Coordinator of this site? Confirm its status | Luxembourg | Luxembourg | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.